IcoSema, a combination therapy of basal insulin icodec and semaglutide, achieves a noninferior reduction in A1c levels compared with basal-bolus therapy in adults with T2D.

The addition of anagliptin to insulin and metformin therapy may improve glycemic control in patients with type 2 diabetes while maintaining an acceptable safety profile.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to ...

Pregnant women with type 1 diabetes who used hybrid closed-loop insulin delivery with Control-IQ technology spent more time ...

More than 8 million people globally suffer from type 1 diabetes, a condition where the immune system destroys ...

In a clinical trial led by University of Toronto researchers, an allogeneic stem cell–derived islet therapy (zimislecel) ...

Amanda Smith has kicked insulin to the curb in what experts are calling a milestone in the fight against Type 1 diabetes.

CHICAGO -- An investigational allogeneic stem cell-derived islet-cell therapy helped almost all patients with type 1 diabetes ...

An off-the-shelf stem cell therapy for type 1 diabetes continues to show positive results, according to a new study.

During a clinical trial, around 83% (10 out of 12) of patients who received a full dose of Zimislecel achieved complete ...